AquaBounty Narrows Q2 Loss to $6.8M Amid Ohio Farm Ramp-Up

TL;DR

**AQB is burning cash with no clear path to profit; avoid until Ohio farm proves viable.**

AI Summary

AquaBounty Technologies Inc. reported a net loss of $6.8 million for the three months ended June 30, 2025, a slight improvement from the $7.1 million net loss in the prior-year period. Revenue for the quarter was not explicitly detailed but the company continues to focus on its genetically engineered salmon production. Key business changes include ongoing operational ramp-up at its Ohio farm, which is crucial for future revenue generation. The company's strategic outlook centers on achieving commercial scale production and market penetration for its AquAdvantage Salmon. Risks include significant capital requirements, potential delays in facility completion, and market acceptance of genetically modified food products. The accumulated deficit reached $331.7 million as of June 30, 2025, indicating substantial historical losses. Cash and cash equivalents stood at $25.3 million, down from $32.1 million at December 31, 2024, highlighting ongoing liquidity needs. The company's ability to continue as a going concern is dependent on securing additional financing and achieving profitable operations.

Why It Matters

AquaBounty's continued losses and significant accumulated deficit of $331.7 million signal a high-risk investment, dependent on the successful commercialization of its AquAdvantage Salmon. For investors, the ability to secure additional financing and achieve profitability at the Ohio farm is paramount, especially given the competitive landscape of traditional aquaculture. Employees' job security hinges on the company's financial viability and operational success. Customers and the broader market are watching to see if genetically engineered salmon can gain widespread acceptance and become a sustainable food source, potentially disrupting the seafood industry.

Risk Assessment

Risk Level: high — The company reported an accumulated deficit of $331.7 million as of June 30, 2025, and a net loss of $6.8 million for the quarter, indicating persistent unprofitability. Cash and cash equivalents decreased from $32.1 million at December 31, 2024, to $25.3 million at June 30, 2025, demonstrating a significant cash burn rate that raises going concern doubts.

Analyst Insight

Investors should exercise extreme caution and consider holding off on AQB shares until there is clear evidence of sustained revenue growth and a path to profitability from the Ohio farm operations. Monitor future filings for updates on production volumes and market acceptance of AquAdvantage Salmon.

Financial Highlights

net Income

-$6.8M

cash Position

$25.3M

Key Numbers

• $6.8M — Net Loss (For Q2 2025, a slight improvement from $7.1M in Q2 2024.)
• $331.7M — Accumulated Deficit (As of June 30, 2025, indicating significant historical losses.)
• $25.3M — Cash and Cash Equivalents (As of June 30, 2025, down from $32.1M at December 31, 2024.)

Key Players & Entities

• AQUABOUNTY TECHNOLOGIES INC (company) — filer of the 10-Q
• SEC (regulator) — recipient of the 10-Q filing
• $6.8 million (dollar_amount) — net loss for the three months ended June 30, 2025
• $7.1 million (dollar_amount) — net loss for the three months ended June 30, 2024
• $331.7 million (dollar_amount) — accumulated deficit as of June 30, 2025
• $25.3 million (dollar_amount) — cash and cash equivalents as of June 30, 2025
• $32.1 million (dollar_amount) — cash and cash equivalents as of December 31, 2024
• Ohio (location) — location of AquaBounty's primary production farm
• AquAdvantage Salmon (product) — AquaBounty's genetically engineered salmon product

FAQ

Risk Factors

• Going Concern Uncertainty [high — financial]: The company's ability to continue as a going concern is dependent on its ability to secure additional financing and achieve profitable operations. The accumulated deficit was $331.7 million as of June 30, 2025, and cash and cash equivalents were $25.3 million, down from $32.1 million at the end of 2024, indicating ongoing liquidity needs.
• Facility Completion Delays [medium — operational]: Ongoing operational ramp-up at the Ohio farm is crucial for future revenue generation. Potential delays in facility completion could significantly impact the company's ability to scale production and meet market demand.
• Market Acceptance of GMO Salmon [medium — market]: The company's strategic outlook centers on market penetration for its AquAdvantage Salmon. Market acceptance of genetically modified food products remains a significant risk that could hinder revenue growth and adoption.
• Significant Capital Requirements [high — financial]: Achieving commercial scale production requires substantial capital investment. The company's current cash position of $25.3 million may be insufficient to fund ongoing operations and expansion without further equity or debt financing.

Industry Context

AquaBounty Technologies operates in the aquaculture industry, focusing on genetically engineered salmon. The industry is increasingly looking for sustainable and efficient protein sources. However, the company faces competition from traditional aquaculture and other alternative protein providers, alongside the unique challenge of consumer acceptance for genetically modified organisms (GMOs).

Regulatory Implications

The company's genetically engineered salmon is subject to strict regulatory oversight in various markets. Navigating these regulations, including labeling requirements and import/export restrictions, is critical for market access and commercialization. Potential changes in regulatory frameworks or public perception of GMOs could significantly impact the business.

What Investors Should Do

1. Monitor cash burn and financing activities.
2. Track progress on Ohio farm ramp-up.
3. Assess market acceptance trends for GMO salmon.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reported net loss of $6.8 million and accumulated deficit of $331.7 million. Cash and cash equivalents stood at $25.3 million.
• 2025-08-05: 10-Q Filing Date — Public filing of the quarterly report, providing detailed financial and operational information for the period ending June 30, 2025.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. (Indicates the company has historically operated at a loss, with a significant deficit of $331.7 million as of June 30, 2025.)

Going Concern

An assumption that a company will continue to operate for the foreseeable future, typically at least the next 12 months. (The company's ability to continue as a going concern is in question, dependent on securing financing and achieving profitability.)

AquAdvantage Salmon

AquaBounty's genetically engineered salmon that grows to market size faster than conventional salmon. (This is the company's primary product, and its commercial scale production and market acceptance are key to future revenue.)

Year-Over-Year Comparison

The net loss for the three months ended June 30, 2025, was $6.8 million, a slight improvement from $7.1 million in the prior-year period. While revenue figures were not explicitly detailed, the company's focus remains on scaling production. Cash and cash equivalents have decreased from $32.1 million at the end of 2024 to $25.3 million as of June 30, 2025, highlighting continued cash burn and the need for financing. No new significant risks were detailed, but existing concerns regarding capital requirements and market acceptance persist.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on August 5, 2025 regarding AQUABOUNTY TECHNOLOGIES INC (AQB).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR